These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

748 related articles for article (PubMed ID: 31004638)

  • 1. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies.
    Venkatramani A; Panda D
    Int J Biol Macromol; 2019 Jul; 133():473-483. PubMed ID: 31004638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.
    Feuillette S; Miguel L; Frébourg T; Campion D; Lecourtois M
    J Neurochem; 2010 May; 113(4):895-903. PubMed ID: 20193038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: essential role for aggregation in neurotoxicity.
    Zhao K; Ippolito G; Wang L; Price V; Kim MH; Cornwell G; Fulenchek S; Breen GA; Goux WJ; D'Mello SR
    J Neurosci Res; 2010 Nov; 88(15):3399-413. PubMed ID: 20882568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
    Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
    Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studying Microtubule Dynamics in Human Neurons: Two-Dimensional Microtubule Tracing and Kymographs in iPSC- and SH-SY5Y-Derived Neurons for Tau Research.
    Allroggen N; Breuer H; Bachmann S; Bell M; Zempel H
    Methods Mol Biol; 2024; 2754():561-580. PubMed ID: 38512690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Embryonic stem cell-based modeling of tau pathology in human neurons.
    Mertens J; Stüber K; Poppe D; Doerr J; Ladewig J; Brüstle O; Koch P
    Am J Pathol; 2013 May; 182(5):1769-79. PubMed ID: 23499461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why Microtubules Should Be Considered as One of the Supplementary Targets for Designing Neurotherapeutics.
    Das G; Ghosh S
    ACS Chem Neurosci; 2019 Mar; 10(3):1118-1120. PubMed ID: 30657675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The microtubule-associated protein tau in neurodegenerative diseases. Tauopathies].
    Sánchez MP; Alvarez-Tallada V; Avila J
    Rev Neurol; 2001 Jul 16-31; 33(2):169-77. PubMed ID: 11562878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infantile tauopathies: Hemimegalencephaly; tuberous sclerosis complex; focal cortical dysplasia 2; ganglioglioma.
    Sarnat HB; Flores-Sarnat L
    Brain Dev; 2015 Jun; 37(6):553-62. PubMed ID: 25451314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.
    Quraishe S; Cowan CM; Mudher A
    Mol Psychiatry; 2013 Jul; 18(7):834-42. PubMed ID: 23587881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
    Brunden KR; Zhang B; Carroll J; Yao Y; Potuzak JS; Hogan AM; Iba M; James MJ; Xie SX; Ballatore C; Smith AB; Lee VM; Trojanowski JQ
    J Neurosci; 2010 Oct; 30(41):13861-6. PubMed ID: 20943926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of tau-induced neurodegeneration.
    Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
    Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tauopathies and tau oligomers.
    Takashima A
    J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of tau protein in both physiological and pathological conditions.
    Avila J; Lucas JJ; Perez M; Hernandez F
    Physiol Rev; 2004 Apr; 84(2):361-84. PubMed ID: 15044677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased acetylation of microtubules rescues human tau-induced microtubule defects and neuromuscular junction abnormalities in
    Mao CX; Wen X; Jin S; Zhang YQ
    Dis Model Mech; 2017 Oct; 10(10):1245-1252. PubMed ID: 28819043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.
    Carlomagno Y; Chung DC; Yue M; Castanedes-Casey M; Madden BJ; Dunmore J; Tong J; DeTure M; Dickson DW; Petrucelli L; Cook C
    J Biol Chem; 2017 Sep; 292(37):15277-15286. PubMed ID: 28760828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau liquid-liquid phase separation: At the crossroads of tau physiology and tauopathy.
    Islam M; Shen F; Regmi D; Petersen K; Karim MRU; Du D
    J Cell Physiol; 2024 Jun; 239(6):e30853. PubMed ID: 35980344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
    Badiola N; Suárez-Calvet M; Lleó A
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo.
    Cowan CM; Bossing T; Page A; Shepherd D; Mudher A
    Acta Neuropathol; 2010 Nov; 120(5):593-604. PubMed ID: 20617325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau, microtubule dynamics, and axonal transport: New paradigms for neurodegenerative disease.
    Cario A; Berger CL
    Bioessays; 2023 Aug; 45(8):e2200138. PubMed ID: 37489532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.